Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group
| Autor: | Verweij, J., Wanders, J., Nielsen, A. L., Pavlidis, N., Calabresi, F., ten Bokkel Huinink, W., Bruntsch, U., Piccart, M., Franklin, H., Kaye, S. B. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Adolescent Antibiotics Antineoplastic/adverse effects/*therapeutic use Carcinoma Non-Small-Cell Lung/drug therapy Ovarian Neoplasms/drug therapy Colorectal Neoplasms/drug therapy Middle Aged Aminoglycosides Drug Administration Schedule Neoplasms/*drug therapy Breast Neoplasms/drug therapy Humans Female Anti-Bacterial Agents/adverse effects/*therapeutic use Lung Neoplasms/drug therapy Aged Follow-Up Studies |
| Popis: | PURPOSE: To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary. PATIENTS AND METHODS: Eligibility required histologically proven cancer. Patients with colorectal or non-small cell lung cancer could not have received prior chemotherapy. Patients were entered if WHO PS was < or = 2 and organ functions were normal. Treatment consisted of Elsamitrucin 25 mg/m2/week given as a 5-10 min infusion for at least 3-6 weekly doses. RESULTS: One hundred and five patients entered the studies, 97 were eligible, 94 are evaluable for toxicity and 75 for response. Toxicity mainly consisted of mild nausea/vomiting, and less frequently reversible hepatotoxicity and malaise. No objective responses were seen. CONCLUSION: Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer. Ann Oncol |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|